To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.
The GLEE initiative will inform and unite K-16 students and educators, public and community-based groups, and healthcare professionals to enhance the integration of genomic information and technologies into healthcare - as well as into society more broadly.
The International Summit in Human Genetics and Genomics is a five-year initiative (2016-2020) designed to help developing nations build and expand their knowledge base, infrastructure, systems and technologies in genetics and genomics. Each fall, researchers from abroad travel to the National Institutes of Health in Bethesda, Maryland for one month of in-person training at the National Human Genome Research Institute (NHGRI). The Summit helps them to understand the prevalence and basis of genetic diseases in their nations and to address these public health challenges. The 2020 Summit will be held on August 31 - October 1, 2020.
The Genome: Unlocking Life’s Code traveling exhibit is on a nationwide tour at museums and science centers across North America to educate and inform the public about genomic science. The exhibit is a partnership of the National Human Genome Research Institute (NHGRI) and the Smithsonian Institution's National Museum of Natural History.
The Genome Research Fund supports genetics and genomics research at the National Human Genome Research Institute (NHGRI).
The Sarcopenia 1 project launched in 2010 and aimed to establish the first evidence-based definition of sarcopenia (muscle weakness), which is still not recognized as a medical condition.
The Biomarkers Consortium’s Bone Quality Project aims to evaluate and to identify biomarkers of bone strength and quality changes by analyzing pooled imaging and biochemical data from multiple clinical studies to allow definition of better clinical endpoints.